Prescott, AZ (PRWEB) June 25, 2013
Dermatologist Robin Fleck, M.D., founder and medical director of Southwest Skin and Cancer Institute, is a featured author in this month’s Vein Therapy News Magazine in which she details a cosmetic laser combination that has proved superior to surgical facelift. Dr. Fleck developed the so-called laser facelift in 2012, by combining AccuLift laser liposuction of the neck and jowls, and the Active FX CO2 fractional resurfacing laser. “Each laser stimulates dermal collagen production at a different level of the skin, so it made sense to couple these lasers to increase skin tightening,” explains Dr. Fleck.
According to the article, the Acculift laser lipo procedure is performed first with removal of fat deposits under the chin and jowls while stimulating collagen in these areas. The procedure is painless and performed with only local anesthesia. Downtime involves just 2-3 days of mild bruising and swelling with patients able to return to work after 2 days. No scars are produced as the laser is introduced through a small needle puncture site.
The next step of this process, which is described in the article, is treatment with the Active FX CO2 fractional resurfacing laser. This second procedure can be performed three to six weeks after the laser lipo procedure and has the advantages of removing age spots and fine lines and wrinkles around crow’s feet and upper lip, as well as tightening skin laxity of the eyes and neck. This laser also improves skin tone and texture and dark circles under the eyes. The Active FX laser requires only topical anesthesia and a ten minute session followed by one week of painless social downtime. No scarring or depigmentation results from the use of this laser.
In contrast, surgical face lift and blepharoplasty under general anesthesia have a lengthy downtime with significant morbidity, and produce surgical scars. Rather than promote the body’s ability to naturally produce collagen, the facelift procedure merely repositions the skin, leaving the same dull appearance, dark circles, age spots and wrinkles above the lip and crow’s feet. Because the facelift is more invasive, patients have an increased risk of bleeding and infection, as well as other risks including nerve damage to the facial muscles and changes in skin sensation. Other consequences can include unevenness of the face, the collection of fluid, irregular skin contour, and an enlarged surgical scar.
The laser facelift’s twofold collagen stimulation produces results nearly equivalent to a surgical facelift within 3-4 months as the skin tightening occurs. Advantages include no scarring, minimal downtime, improvement in the condition, tone and texture of the skin, avoidance of general anesthesia, and a price tag which is approximately one-third the cost of a surgical procedure. The laser facelift can be incorporated with Botox, platelet rich plasma injections, and dermal fillers for maximal cosmetic restoration.
Although this procedure has proven to be successful in her hands, in the article, Dr. Fleck warns that candidates should always be screened with a thorough examination. Patients should take into account social behaviors, like smoking, reversing the benefits of the FX laser. These patients would not be ideal candidates for the procedure. Furthermore, patients who take aspirin or over the counter supplements like fish oil or vitamin E should discontinue these products for two weeks prior to the procedure to avoid excessive bleeding after each procedure.
Cosmetic dermatologist, Robin Fleck, M.D., is a double board certified dermatologist and internist, recognized by the American Board of Dermatology and the American Board of Internal Medicine. She is founder and Medical Director of Southwest Skin and Cancer Institute and Body Oasis Laser Aesthetics http://www.rejuvadoc.com. Dr. Fleck is a fellow of the American Society of Laser Medicine and Surgery and the American Academy of Dermatology. Dr. Fleck is also the director of Vein Specialties in Prescott, Arizona and is a member of the American Venous Forum.
Read the full story at http://www.prweb.com/releases/2013/6/prweb10762530.htm.
Copyright©2012 Vocus, Inc.
All rights reserved